Head-To-Head Survey: Oramed Pharmaceuticals (NASDAQ:ORMP) vs. CollPlant Biotechnologies (NASDAQ:CLGN)

Oramed Pharmaceuticals (NASDAQ:ORMP) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Oramed Pharmaceuticals and CollPlant Biotechnologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0	1	0	0	2.00
CollPlant Biotechnologies	1	1	0	0	1.50

CollPlant Biotechnologies has a consensus price target of $120.00, suggesting a potential upside of 2,869.56%. Given CollPlant Biotechnologies’ higher probable upside, analysts plainly believe CollPlant Biotechnologies is more favorable than Oramed Pharmaceuticals.

Profitability

This table compares Oramed Pharmaceuticals and CollPlant Biotechnologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%
CollPlant Biotechnologies	-678.37%	-298.21%	-167.83%

Earnings & Valuation

This table compares Oramed Pharmaceuticals and CollPlant Biotechnologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2.00 million	86.22	$64.05 million	$4.12	1.01
CollPlant Biotechnologies	$2.37 million	3.22	-$11.49 million	($13.59)	-0.30

Oramed Pharmaceuticals has higher earnings, but lower revenue than CollPlant Biotechnologies. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 20.8% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Oramed Pharmaceuticals has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, CollPlant Biotechnologies has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500.

Summary

Oramed Pharmaceuticals beats CollPlant Biotechnologies on 9 of the 13 factors compared between the two stocks.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.